Sulfatinib (KDR-IN-1, HMPL-012) is a highly selective small molecule inhibitor targeting VEGFR1/2/3, FGFR1, and CSF1R with potent activity in the low nanomolar range. It is a valuable research tool for investigating angiogenesis, tumor microenvironment, and related signaling pathways in both cellular and animal models of cancer and inflammatory diseases.